ArticleBMC infectious diseases2026
Diagnostic value of integrated albumin-to-leukocyte ratio risk modeling stratification and machine learning approaches for prediction of spontaneous bacterial peritonitis in cirrhotic patients.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpontaneous bacterial peritonitis (SBP) remains a life-threatening complication of liver cirrhosis, requiring accurate and rapid prediction. Albumin and leukocyte count reflect systemic inflammation and liver dysfunction; combining them into an Albumin-to-Leukocyte Ratio (ALR) may enhance early risk stratification.
aimTo evaluate the diagnostic value of the ALR for predicting SBP in patients with cirrhosis and develop an ALR-based risk score. We will compare its predictive accuracy with machine-learning models to establish a practical triage tool for SBP risk stratification. PATIENT AND
methodsThis cross-sectional study included 240 cirrhotic patients, categorized into SBP (n = 152) and non-SBP (n = 88). Demographic, clinical, hematological, and biochemical variables were analyzed. ALR was calculated, and its predictive accuracy was assessed using ROC curves. A risk score integrating ALR, hemoglobin, bilirubin, and Child-Pugh class was generated. Logistic regression identified independent predictors. Diagnostic performance of ALR was compared with decision tree and random forest models.
resultsSBP patients had significantly lower albumin, ALR, hemoglobin, and platelets, and higher leukocyte count, bilirubin, INR, and creatinine (all p ≤ 0.05). ALR demonstrated moderate diagnostic performance with fair discrimination; AUC of 0.707, achieving a sensitivity of 82% at a cutoff of ≤ 0.728. Multivariate analysis identified ALR (OR = 0.114, p = 0.001), hemoglobin (OR = 0.847, p = 0.024), bilirubin (OR = 1.319, p = 0.004), MELD score (OR = 0.998, p = 0.042) and Child-Pugh class C (OR = 4.86, p = 0.001) as independent predictors. The generated ALR risk score (0-7 points) categorized patients into low, intermediate, and high-risk groups with increasing diagnostic accuracy (AUC range 0.63-0.75). Machine-learning models outperformed ALR alone; random forest showed the highest discrimination (AUC = 0.901), followed by decision tree (AUC = 0.852).
conclusionALR is a simple and accessible biomarker with moderate accuracy for predicting SBP in cirrhotic patients and may serve as a practical bedside triage tool when integrated into a composite risk score. However, machine-learning models, particularly random forest, demonstrated superior predictive performance, suggesting that combining conventional biomarkers with advanced algorithms may enhance SBP risk stratification. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.